Dr. Andrew Aguirre is a medical oncologist at Dana-Farber Cancer Institute, an Assistant Professor of Medicine at Harvard Medical School and an Institute Member at the Broad Institute of Harvard and MIT. Dr. Aguirre sees patients and leads a cancer research laboratory that studies RAS signaling and pancreatic cancer biology with the goal of developing new therapeutic strategies for patients.
Dr. Aguirre’s laboratory utilizes functional genetic tools to identify new therapeutic targets in cancer, with a specific focus on pancreatic cancer. Leveraging patient-derived models, the lab characterizes mechanisms of response and resistance to new cancer therapeutics and develops combination therapy approaches for study in preclinical models and clinical trials. Dr. Aguirre is active in clinical trial design and translational studies from patient biopsies.
Dr. Aguirre is an elected member of the American Society for Clinical Investigation and has won multiple awards, including the Wilson S. Stone Award from MD Anderson Cancer Center, AACR NextGen Stars Award, an ASCO Young Investigator Award, and the William Guy Forbeck Foundation Scholar Award.